By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Help Your Insusceptibility: Good dieting and Way of life Tips - 2US measles cases surpass 2,000, highest in 30 years: CDC
- 3Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- 4Reconnecting with an old friend is a story of distance, loss and rediscovery
- 5The Best Cell phone Brands for Tech Lovers
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- The race to mine the moon is on – and it urgently needs some clear international rules
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Eight Muslim nations condemn Israel's 'dangerous' new death penalty law
